Mucosal Expression of Type 2 and Type 17 Immune Response Genes Distinguishes Ulcerative Colitis From Colon-Only Crohn's Disease in Treatment-Naive Pediatric Patients by Rosen, M.J. et al.
Mucosal Expression of Type 2 and Type 17 Immune Response
Genes Distinguishes Ulcerative Colitis From Colon-Only Crohn’s
Disease in Treatment-Naive Pediatric Patients
Michael J. Rosen,1,2 Rebekah Karns,1 Jefferson E. Vallance,1 Ramona Bezold,1
Amanda Waddell,1 Margaret H. Collins,3,4 Yael Haberman,1,5 Phillip Minar,1,2
Robert N. Baldassano,6 Jeffrey S. Hyams,7 Susan S. Baker,8 Richard Kellermayer,9
Joshua D. Noe,10 Anne M. Griffiths,11 Joel R. Rosh,12 Wallace V. Crandall,13
Melvin B. Heyman,14 David R. Mack,15 Michael D. Kappelman,16 James Markowitz,17
Dedrick E. Moulton,18 Neal S. Leleiko,19 Thomas D. Walters,11 Subra Kugathasan,20
Keith T. Wilson,21,22 Simon P. Hogan,2,23 and Lee A. Denson1,2
1Division of Gastroenterology, Hepatology and Nutrition, 3Division of Pathology, 23Division of Allergy and Immunology, 
Cincinnati Children’s Hospital Medical Center, Cincinnati, Ohio; 2Department of Pediatrics, 4Department of Pathology and 
Laboratory Medicine, University of Cincinnati College of Medicine, Cincinnati, Ohio; 5Pediatric Gastroenterology Unit, The 
Edmond and Lily Safra Children’s Hospital, Sheba Medical Center, Tel Hashomer, Israel; 6Division of Pediatric 
Gastroenterology, Hepatology and Nutrition, Children’s Hospital of Philadelphia, Philadelphia, Pennsylvania; 7Division of 
Digestive Diseases, Hepatology, and Nutrition, Connecticut Children’s Medical Center, Hartford, Connecticut; 8Digestive 
Diseases and Nutrition Center, Women and Children’s Hospital of Buffalo, Buffalo, New York; 9Department of Pediatrics, 
Section of Pediatric Gastroenterology, Hepatology and Nutrition, Baylor College of Medicine, Houston, Texas; 10Division of 
Gastroenterology, Hepatology and Nutrition, Department of Pediatrics, Medical College of Wisconsin, Milwaukee, Wisconsin; 
11Division of Gastroenterology, Hepatology and Nutrition, The Hospital for Sick Children, Toronto, Canada; 12Goryeb 
Children’s Hospital/Atlantic Health, Icahn School of Medicine at Mount Sinai, New York, New York; 13Division of Pediatric 
Gastroenterology, Hepatology and Nutrition, Nationwide Children’s Hospital, Columbus, Ohio; 14Division of Pediatric 
Gastroenterology, Hepatology and Nutrition, University of California San Francisco, San Francisco, California; 15Department 
of Pediatrics and Children’s Hospital of Eastern Ontario Inflammatory Bowel Disease Centre, Children’s Hospital of Eastern 
Ontario, Ottawa, Ontario, Canada; 16Division of Pediatric Gastroenterology, Department of Pediatrics, University of North 
Carolina at Chapel Hill, Chapel Hill, North Carolina; 17Division of Pediatric Gastroenterology and Nutrition, Cohen Children’s 
Medical Center of New York, New Hyde Park, New York; 18Division of Gastroenterology, Hepatology, and Nutrition, 
Department of Pediatrics, Vanderbilt University School of Medicine, Nashville, Tennessee; 19Division of Pediatric 
Gastroenterology, Nutrition and Liver Diseases, Hasbro Children’s Hospital, Providence, Rhode Island; 20Division of 
Gastroenterology, Hepatology and Nutrition, Department of Pediatrics, Emory University, Atlanta, Georgia; 21Division of 
Gastroenterology, Hepatology and Nutrition, Department of Medicine, Vanderbilt University Medical Center, Nashville, 
Tennessee; 22Veterans Affairs Tennessee Valley Healthcare System, Nashville, TennesseeBACKGROUND & AIMS: There is controversy regarding the
role of the type 2 immune response in the pathogenesis of
ulcerative colitis (UC)—few data are available from
treatment-naive patients. We investigated whether genes
associated with a type 2 immune response in the intestinal
mucosa are up-regulated in treatment-naive pediatric pa-
tients with UC compared with patients with Crohn’s disease
(CD)-associated colitis or without inflammatory bowel dis-
ease (IBD), and whether expression levels are associated
with clinical outcomes. METHODS: We used a real-time
reverse-transcription quantitative polymerase chain reac-
tion array to analyze messenger RNA (mRNA) expression
patterns in rectal mucosal samples from 138 treatment-naive
pediatric patients with IBD and macroscopic rectal disease,
as well as those from 49 children without IBD (controls),
enrolled in a multicenter prospective observational study
from 2008 to 2012. Results were validated in real-time
reverse-transcription quantitative polymerase chain reac-
tion analyses of rectal RNA from an independent cohort of 34pediatric patients with IBD and macroscopic rectal disease
and 17 controls from Cincinnati Children’s Hospital Medical
Center. RESULTS: We measured significant increases in
mRNAs associated with a type 2 immune response (inter-
leukin [IL]5 gene, IL13, and IL13RA2) and a type 17 immune
response (IL17A and IL23) in mucosal samples from patients
with UC compared with patients with colon-only CD. In a
regression model, increased expression of IL5 and IL17A
mRNAs distinguished patients with UC from patients with
colon-only CD (P ¼ .001; area under the receiver operating
characteristic curve, 0.72). We identified a gene expression
pattern in rectal tissues of patients with UC, characterized by
detection of IL13 mRNA, that predicted clinical response to
therapy after 6 months (odds ratio [OR], 6.469; 95% confi-
dence interval [CI], 1.553–26.94), clinical response after 12
months (OR, 6.125; 95% CI, 1.330–28.22), and remission
after 12 months (OR, 5.333; 95% CI, 1.132–25.12).
CONCLUSIONS: In an analysis of rectal tissues from
treatment-naive pediatric patients with IBD, we observed
activation of a type 2 immune response during the early
course of UC. We were able to distinguish patients with UC
from those with colon-only CD based on increased mucosal
EDITOR’S NOTES
BACKGROUND AND CONTEXT
There is controversy over the role of the type 2 immune
response in pathogenesis of ulcerative colitis (UC)—few
data are available from treatment-naïve patients.
NEW FINDINGS
The researchers showed that treatment-naïve pediatric
patients with ulcerative colitis exhibit increased mucosal
expression of genes associated with type 2 and type 17
immune responses compared to those with colon-only
Crohn’s disease.
LIMITATIONS
This study measured only mRNA expression and not
protein abundance.
IMPACT
Expression of type 2 and type 17 immune response genes
distinguishes ulcerative colitis from colon-only Crohn’s
disease in treatment-naïve pediatric patients.expression of genes that mediate type 2 and type 17 immune
responses. Increased expression at diagnosis of genes that
mediate a type 2 immune response is associated with
response to therapy and remission in pediatric patients
with UC.Keywords: Immune Regulation; Gene Expression Profile; Prog-
nostic Factor; AUROC.
ype 2 inflammation has been implicated in the
1,2Abbreviations used in this paper: CD, Crohn’s disease; CDc, colon-only
Crohn’s disease; CDic, ileocolonic Crohn’s disease; CI, confidence
interval; Cq, quantification cycle; IBD, inflammatory bowel disease; ICOS,
inducible t-cell costimulator; IFNG, interferon-g; IL, interleukin; OR, odds
ratio; PGA, physician’s global assessment; RHI, Robarts Histopathology
Index; RISK, Risk Stratification and Identification of Immunogenetic and
Microbial Markers of Rapid Disease Progression in Children with Crohn’s
Disease; RT-qPCR, quantitative reverse-transcription polymerase chain
reaction; TNF, tumor necrosis factor; UC, ulcerative colitis.Tpathogenesis of ulcerative colitis (UC). Classic
type 2 immune responses are defined by production of the
cytokines interleukin (IL)4, IL5, and IL13 by T helper cells
and innate lymphoid cells and are involved in the expulsion
of helminths and the pathogenesis of allergic diseases.3 UC,
however, has been associated with an atypical type 2 im-
mune response, with increased IL5 and IL13, but not IL4.2
Further studies have indicated pathogenic effects of IL13
including activation of inflammatory colon mucosal natural
killer T cells and impairment of epithelial barrier function.4
The initial observation of this atypical type 2 immune
response in UC originated from ex vivo experiments with
lamina propria immune cells isolated from surgical speci-
mens from adults with IBD.2 Whether type 2 inflammation
is involved in UC patients at diagnosis, before treatments
that affect the inflammatory response, or in pediatric UC
remains unknown. Furthermore, it is unknown if patients
with heightened type 2 inflammatory responses attain
different clinical outcomes.
Distinguishing UC from Crohn’s colitis can be a diag-
nostic challenge in pediatric patients. Regardless of diag-
nosis with UC or Crohn’s disease (CD), a colitis phenotype is
a common feature of pediatric IBD. UC and inflammatory
bowel disease (IBD) unclassified account for 30%–40% of
pediatric IBD in the United States and Europe.5–7 Further-
more, approximately 80% of children with CD have colonicinvolvement, with 25% showing a colon-only phenotype
with no small intestinal involvement.8,9 Colon-only CD
phenotype is even more common with younger age, occur-
ring in approximately 40% of children younger than 10
years of age.8,9 Taken together, approximately 50% of
pediatric IBD patients show an isolated colitis phenotype.
Many of these children show overlapping or atypical fea-
tures, which hinder rendering a specific diagnosis of CD or
UC.10 It is not known whether mucosal expression of genes
associated with type 2 inflammation can distinguish UC and
CD pediatric patients with isolated colitis phenotypes.
We hypothesized that treatment-naive pediatric patients
with UC would show increased mucosal type 2 immune
responses compared with patients without IBD and Crohn’s
colitis, and that high expression of type 2–associated genes
would be associated with poor response to therapy in pe-
diatric UC. Here, we applied a microfluidic real-time
reverse-transcription quantitative polymerase chain reac-
tion (RT-qPCR) array platform to determine rectal mucosal
expression of genes associated with type 1, type 2, and type
17 inflammation in patients with UC, Crohn’s colitis, and
non-IBD controls from a large multicenter North American
pediatric IBD inception cohort. We report that expression of
genes associated with type 2 and type 17 immune responses
distinguished 2 colon-only phenotypes of pediatric IBD: UC
and colon-only CD. Furthermore, we observed that a gene
expression profile marked by detectable IL13 expression is
associated with improved clinical outcomes in pediatric UC.
Materials and Methods
RISK Cohort Rectal RNA Samples
Rectal mucosal RNA samples from treatment-naive IBD
patients and non-IBD controls and associated clinical data were
obtained from the Risk Stratification and Identification of Im-
munogenetic and Microbial Markers of Rapid Disease Pro-
gression in Children with Crohn’s Disease (RISK) study, a
prospective observational IBD inception cohort sponsored by
the Crohn’s and Colitis Foundation. A total of 1812 children and
adolescents younger than age 17, newly diagnosed with IBD
and non-IBD controls, were enrolled at 28 North American
pediatric gastroenterology centers between 2008 and 2012. All
participants underwent baseline colonoscopy with confirma-
tion of characteristic chronic active colitis and/or ileitis by
histology before diagnosis and treatment. Institutional Review
Board approval was obtained locally at each participating site.
All endoscopic tissues obtained in the RISK study were stored
in RNALater (Thermo Fisher Scientific, Waltham, MA), thus
RNA and DNA, but not protein, are available for study. This 
analysis included a representative subgroup of RISK partici-
pants with UC (n ¼ 56), colon-only CD (CDc, n ¼ 36), ileoco-
lonic CD (CDic, n ¼ 46), and non-IBD controls (n ¼ 49). This 
constitutes all participants within RISK with rectal RNA who 
met study criteria for UC and CDc, and a random sample of 
those who met study criteria for CDic. Only patients with a 
confirmed diagnosis of CD, UC, or non-IBD based on standard 
clinical and pathologic criteria after a median of 3.3 years of 
follow-up evaluation were included in this analysis. To meet the 
study definition of CD in RISK, patients eventually must have 
been found to have at least 2 of the following: signs or symp-
toms consistent with CD (diarrhea, abdominal pain, rectal 
bleeding, malaise, weight loss, or linear growth failure), endo-
scopic findings of discontinuous ulceration or cobblestoning, 
and/or histopathologic findings of patchy inflammatory cell 
infiltrates or epithelial granuloma. Detailed granular data 
regarding anatomic disease involvement was obtained for all 
participants in the RISK cohort. For the purposes of this anal-
ysis, all participants with UC and CD must have shown 
macroscopic inflammation in the rectum at the time of 
biopsy collection. Participants with UC must have received a 
most recent diagnosis of UC, shown macroscopic inflammation 
in the rectum (because RNA analyzed in this study was isolated 
from rectal biopsy specimens), absence of macroscopic 
inflammation in the ileum at their enrollment endoscopy, and 
absence of evidence of jejunal inflammation. Participants with 
CDc must have received a most recent diagnosis of CD and 
shown macroscopic inflammation in the rectum with an 
absence of macroscopic inflammation in the ileum or jejunum. 
Participants with CDic must have received a most recent 
diagnosis of CD and shown macroscopic inflammation in both 
the rectum and ileum. Non-IBD control participants must have 
received a most recent diagnosis of non-IBD and shown 
macroscopically and microscopically normal ileum and colon.Cincinnati Cohort
Under a protocol approved by the Cincinnati Children’s 
Hospital Medical Center Institutional Review Board, patients 
presenting for routine colonoscopy for clinical indications were 
enrolled in a separate independent local Cincinnati cohort for 
the purposes of validating the findings from the RISK cohort. 
Patients in the Cincinnati cohort were not in the RISK cohort. 
Clinical information was collected at the time of enrollment. 
Rectal biopsy specimens were placed in RNALater and stored at
-80C. Only patients with macroscopic inflammation in the 
rectum at endoscopy were included in the analysis. H&E-
stained sections from rectal biopsy specimens were scored by a 
pediatric pathologist blinded to diagnosis using the validated 
Robarts Histopathology Index (RHI).11Real-Time RT-qPCR
For all RISK cohort RNA samples studied, rectal RNA 
integrity was determined using an Agilent 2100 Bioanalyzer 
instrument (Agilent Technologies, Santa Clara, CA). Only 
samples with an RNA integrity number of 7 or greater were 
included (95.5% of samples tested). The expression of 24 genes 
related to type 2, type 1, type 17, and regulatory immune re-
sponses (Supplementary Table 1) was determined by quanti-
tative real-time RT-qPCR in duplicate from 100 ng starting RNAusing custom TaqMan array 384-well microfluidic cards on a
7900HT Real-Time PCR System (Thermo Fisher Scientific). The
endogenous reference control was selected empirically by
analyzing a subset of 16 samples (4 from each diagnosis group)
with the TaqMan Human Endogenous Control Array (Thermo
Fisher Scientific), which assesses expression of 16 genes
known to show minimal differential expression across tissues.
Real-time RT-qPCR on rectal RNA from the Cincinnati cohort
was performed using a subset of individual gene expression
assays from the custom microfluidic array. Relative expression
was determined using a modification of the 2-DDCq method as
previously described.12 Briefly, changes in the quantification
cycle (DCq) values were obtained by subtracting the target Cq
from that of the reference gene. DCq values then were shifted
such that expression in samples with undetectable expression
(Cq > 40) was considered half that of the sample with the least
detectable expression.Outcomes
Outcomes assessed in the UC group included steroid-free,
surgery-free clinical response and clinical remission at 6 and
12 months. Clinical remission was defined as a physician
global assessment (PGA) of inactive disease. The 4 PGA cate-
gories were inactive mild, moderate, and severe disease. Clin-
ical response was defined as a PGA of inactive or mild disease,
with at least a 1-category decrease in PGA between baseline
and the indicated time point (ie, if the patient had mild disease
at baseline, they must have improved to inactive disease). For
both end points, patients must have been off systemic corti-
costeroids, with no prior surgery at the indicated time point.Statistical Analysis
Statistical analyses were performed using SAS v9.3 (SAS
Institute, Cary, NC). For gene expression array data from the
RISK cohort, we assessed global differences in expression for
each gene among the 4 diagnosis groups using the nonpara-
metric Kruskal–Wallis H test with false-discovery rate to
control the type 1 error rate at 0.05. We then performed
pairwise comparisons between diagnosis groups only for genes
passing the omnibus test using the Mann–Whitney U test with
false-discovery rate correction. Correlation of expression be-
tween genes was assessed by the Spearman rank correlation
coefficient. Principal component analysis incorporating all
array gene expression data was performed using Genespring
GS (Agilent Technologies). We applied unsupervised hierar-
chical clustering (Genespring GS) to identify patient clusters
with unique gene expression patterns. To validate gene
expression differences discovered in the RISK cohort in the
independent Cincinnati cohort, we compared expression of
selected genes and RHI using the Kruskal–Wallis H test fol-
lowed by pairwise comparisons using the Mann–Whitney
U test only if the omnibus test was significant. In a sensitivity
analysis to control for histologic disease activity within the
local Cincinnati cohort, patients with CD and UC were matched
on RHI (within 1 point) and gene expression was compared
using the Wilcoxon signed-rank test. We assessed the perfor-
mance of gene expression to distinguish UC from CDc and to
predict clinical outcomes in UC patients using logistic regres-
sion. The regression model for distinguishing UC from CDc was
validated internally across 1000 random samples of equal size
using a random sampling with replacement bootstrap tech-
nique. To assess the contribution of degree of inflammation to 
the observed differences in gene expression between UC and 
CDc, bivariate logistic regression was performed for each target 
gene with significant differences in gene expression between 
UC and CDc and S100A8. A change in effect estimate between 
univariate and bivariate analysis with S100A8 of less than 10%, 
10%–20%, or greater than 20% were interpreted as no, mild, 
or moderate confounding by S100A8, respectively.13 S100A8 
was forced into the final multivariate model for predicting UC 
from CDc to determine the contribution of the degree of 
inflammation to the final model. Baseline characteristics among 
gene expression patient clusters were compared using 
the Kruskal–Wallis H test for continuous variables or the 
chi-square test for nominal variables. The association between 
gene expression cluster and clinical outcomes in the UC group 
was assessed by the Fisher exact test.
Sample Size and Power
We determined that a sample size of 40 patients per diag-
nosis group would provide 90% power to detect a 1.5-fold 
difference in expression while controlling the type I error 
rate at 1% for multiplicity.Results
RISK Cohort Rectal Mucosal Gene Expression
Demographics and baseline characteristics of the subset 
of the RISK cohort participants studied for this analysis are 
detailed in Table 1. There were no meaningful differencesTable 1.Baseline Characteristics of RISK Cohort Patients Stud
Non-IBD (n ¼
Age, y 12.8 (10.8, 1
A1a: 0–<10 y
A1b: 10–<17 y
Male sex 23 (46.9)
CD location
L1: terminal ileal ± limited cecal disease
L2: colonic
L3: ileocolonic
L4a: upper disease proximal to ligament of Treitz















NOTE. Quantitative variables are expressed as medians (quartile
PUCAI, Pediatric Ulcerative Colitis Activity Index.between the subset of RISK cohort patients included in this
study and the overall RISK cohort other than for charac-
teristics within the specific inclusion or exclusion criteria
for this study (Supplementary Table 2). All participants
with CDic, CDc, and UC in the studied subset showed
macroscopic rectal inflammation at endoscopy, compared
with 67.5%, 74.8%, and 88.5%, respectively, in the overall
RISK cohort (relative rectal sparing can be an atypical
feature of pediatric UC). We only included participants
showing macroscopic rectal inflammation to limit the effect
of differences in rectal inflammation on the analysis. In
addition, no patients in the studied subset of CDc partici-
pants showed jejunal inflammation compared with 9.5% of
CDc participants in the overall RISK cohort. Although jejunal
involvement (Paris L4b) does not preclude the designation
of colon-only CD (Paris L2) based on the Paris classifica-
tion,14 we excluded participants with jejunal disease from
our CDc group because these patients can be distinguished
easily from UC patients based on anatomic disease distri-
bution alone.
Among 16 candidate reference gene controls assessed,
glyceraldehyde-3-phosphate dehydrogenase showed the
least variable expression across diagnosis groups (SD of
Cq, 0.55), and was included in the gene expression array as
the endogenous control against which we normalized
results (Supplementary Figure 1).
The rectal relative expression of the 22 genes assayed
normalized to the median of non-IBD patients is detailed in
Figure 1A (the assay for CLDN2 did not amplify and is
excluded from the results). Compared with non-IBDied
49) CDic (n ¼ 46) CDc (n ¼ 36) UC (n ¼ 56)
5) 12.4 (10.9, 13.6) 12.7 (10.8, 14.5) 13.5 (10.8, 15.5)
11 (23.9) 6 (17.1) 13 (23.2)
35 (76.1) 30 (85.7) 43 (76.8)
25 (54.3) 17 (47.2) 30 (53.6)
0 (0) 0 (0)
0 (0) 36 (100)
46 (100) 0 (0)
32 (69.6) 17 (47.2)






46 (100) 36 (100) 56 (100)
0 (0) 1 (2.8) 1 (1.8)
11 (23.9) 7 (19.4) 20 (35.7)
22 (47.8) 19 (52.8) 23 (41.1)
13 (28.3) 9 (25.0) 12 (21.4)
45 (35, 60)
5 (10.9) 12 (33.3) 10 (17.9)
1, quartile 3), and dichotomous variables are shown as n (%).
patients, UC patients were the only group that showed 
significantly increased rectal expression of the genes for the 
type 2 cytokines IL5 and IL13 (no group showed signifi-
cantly increased expression of IL4). IL17A and IL23A were 
increased significantly in UC and CDc, but not in CDic, 
compared with non-IBD. Interferon-g and IL22 expression 
were increased similarly in all 3 groups compared with 
non-IBD.
Compared with CDc patients with macroscopic rectal 
involvement, UC patients showed significantly increased 
rectal expression of genes associated with type 2 ([IL5, IL13, 
IL13RA2, inducible t-cell costimulator [ICOS], and the tran-
script for membrane-bound IL33 receptor, IL1RL1[m]) and 
type 17 (IL17A, IL23A) immune responses. Of note, 
expression of the inflammatory marker S100A8, which en-
codes a subunit of calprotectin, was not significantly 
different between UC and CDc patients.
Consistent with the finding of increased IL13 and IL17A 
expression in UC patients, we observed moderate correla-
tion (r2 ¼ .18; P < .0001) between IL13 and IL17A 
expression among all IBD patients. However, among UC 
patients, we observed no significant correlation between 
IL13 and IL17A expression (r2 ¼ .057; P ¼ .076).
Principal component analysis (Figure 1B), incorporating 
all genes analyzed, identified 2 groups of patients. Group 1 
included most of the UC and CDc patients, and group 2 
included most of the non-IBD patients. CDic patients were 
intermixed between the 2 principal component groups.
Unsupervised hierarchical clustering segregated patients 
into 5 clusters based on gene expression (Figure 1C). The 
largest aggregate of a single diagnosis was UC patients 
within cluster 2, which was defined by high expression of 
IL13 and IL5, and also high expression of CCL11, IL13RA2, 
CHI3L1, S100A8, IL23A, and IL17A. Cluster 2 was composed 
of 59.1% UC patients (46.4% of all the UC patients) and 
6.8% non-IBD patients. The remaining clusters were defined 
by differences in IL5 and IL13 expression, with more vari-
able and lower expression of the remaining genes compared 
with cluster 2. Cluster 4, which showed undetectable 
expression of IL5 and IL13, comprised the largest group of 
non-IBD patients (43.5% non-IBD, 40.8% of all the non-IBD 
patients). This unequal distribution of diagnoses among the 
clusters was statistically significant, whereas other baseline 
characteristics were similar (Table 2).Validation of RISK Cohort Differential Rectal 
Gene Expression in the Cincinnati Cohort
Demographics and baseline characteristics of patients in 
the Cincinnati cohort are detailed in Supplementary Table 3. 
Rectal biopsy specimens were analyzed from 17 non-IBD, 
20 CD, and 14 UC patients. All CD and UC patients showed 
macroscopic inflammation in the rectum. Similar to the RISK 
Cohort, UC patients in our Cincinnati cohort showed 
increased rectal expression of IL5, IL13, IL13RA2, IL17A, and 
IL23A compared with CD patients with colitis and non-IBD 
patients (Figure 2A). Also consistent with the RISK cohort 
findings, UC and CD patients showed similarly increased 
IFNG expression compared with non-IBD patients.We sought to compare rectal histopathologic disease
activity between the macroscopically involved rectums of
CD and UC patients in the Cincinnati cohort, acknowledging
the challenge that no histopathologic index exists that has
been validated for pediatric UC or CD, or for comparing
between CD and UC patients. Therefore, histopathologic
activity was compared between patient groups using the
RHI, a validated UC index that assesses the following fea-
tures common to both UC and CD: chronic inflammatory
infiltrate, lamina propria neutrophils, neutrophils in the
epithelium, and erosion or ulceration.11 The median RHI
was significantly higher in the macroscopically inflamed
rectums of UC compared with CD patients (Supplementary
Figure 2A). Therefore, to determine whether differences in
gene expression are explained by differences in histopath-
ologic severity, we performed a sensitivity analysis
comparing gene expression between a subset of 10 UC and
CD patients matched on RHI (Supplementary Figure 2B and C).
In this smaller subset of RHI-matched patients, there was
significantly increased rectal relative expression of IL13 and
IL13RA2 in UC compared with CD patients. Furthermore,
other gene expression relationships between UC and CD
were maintained with numerically (but not statistically
significantly) increased relative expression of IL17A, IL23A,
and IL5, and equivalent IFNG expression in UC compared
with CD.
To determine if healing on treatment is associated with
changes in IL13 and IL17A expression, we compared
mucosal gene expression between UC patients in the Cin-
cinnati cohort, all with active endoscopic disease, with 3
additional UC patients with complete mucosal healing on
treatment (Mayo endoscopic score, 0; all female; ages 7, 9,
and 20 years; healing achieved on 6-mercaptopurine þ
infliximab, mesalamine alone, and mesalamine and oral
corticosteroids, respectively). Both IL13A and IL17A
expression were decreased significantly in the patients with
mucosal healing compared with those with active endo-
scopic disease (Figure 2B).IL5 and IL17 Expression Distinguish UC From
Colitis-Only CD
To determine the ability of gene expression to discrim-
inate UC from CDc, we applied univariate logistic regression
using only the genes with significant differential expression
between UC and CDc (Supplementary Table 4). Using
multivariate logistic regression, we determined that a model
including IL5 and IL17A gene expression best balanced
parsimony with discriminatory ability (P ¼ .001; area under
the curve, 0.72) (Table 3 and Figure 3A). We internally
validated the model using bootstrap random sampling with
replacement and showed that the bootstrapped estimates
for the odds ratios (ORs) for both IL5 and IL17A were sig-
nificant with 95% confidence intervals (CIs) not crossing 1
(Figure 3B).
Although there was not a significant difference in
S100A8 expression between UC and CDc, we sought to
determine the degree to which differences in other genes
were confounded by general inflammatory activity. For
genes that showed significantly different expression 
between UC and CDc, we compared the effect estimate ob-
tained by univariate analysis with that obtained by bivariateanalysis with S100A8 (Supplementary Table 5). We detected
no evidence of confounding by S100A8 (<10% change in
effect estimate) for IL5, IL1RL1(m), IL17A, and IL23A,
Table 2.Comparison of Baseline Characteristics Between Gene Expression Patient Clusters
Gene expression cluster
P value1 (n ¼ 25) 2 (n ¼ 44) 3 (n ¼ 39) 4 (n ¼ 46) 5 (n ¼ 27)
Age, y 12.1 (9.3, 14.8) 12.8 (9.4, 15.4) 13.8 (10.7, 15.2) 12.3 (10.8, 14.8) 12.9 (11.3, 15.2) .757
Male sex 11 (44.0) 23 (52.3) 25 (64.1) 28 (60.9) 12 (44.4) .342
Diagnosis
Non-IBD 6 (24.0) 3 (6.8) 9 (23.1) 20 (43.5) 7 (25.9) <.001
CDic 8 (32.0) 9 (20.5) 11 (28.2) 10 (21.7) 8 (29.6)
CDc 4 (16.0) 6 (13.6) 12 (30.8) 8 (17.4) 6 (22.2)
UC 7 (28.0) 26 (59.1) 7 (17.9) 8 (17.4) 6 (22.2)
PGA
Inactive 0 (0) 1 (2.4) 0 (0) 1 (3.8) 0 (0) .119a
Mild 3 (15.8) 17 (41.5) 7 (23.3) 6 (23.1) 5 (25.0)
Moderate 14 (73.7) 13 (31.7) 15 (50.0) 10 (38.5) 10 (50.0)
Severe 2 (10.5) 10 (24.4) 8 (26.7) 9 (34.6) 5 (25.0)
Rectal deep ulcers 4 (21.1) 7 (17.1) 6 (20.0) 6 (23.1) 3 (15.0) .957
NOTE. Quantitative variables are expressed as medians (quartile 1, quartile 3), and dichotomous variables are shown as n (%).
Bold text indicates P < .05.
aInactive and mild combined for chi-square test.evidence of only mild confounding (10%–20% change) for 
IL13, and evidence of moderate confounding (20%–30%) 
for IL13RA2 and ICOS. Furthermore, when S100A8 is forced 
into our final model with IL5 and IL17A, S100A8 does not 
contribute any predictive value for UC over CDc to the 
model, and the overall model characteristics and perfor-
mance are unchanged with an unchanged area under the 
curve of 0.72 (Supplementary Table 6).Gene Expression Predicts Clinical Outcome in 
UC Patients
Of the 56 UC patients in the RISK cohort we studied, 
outcome data were available for 44 and 37 patients at 6 
and 12 months, respectively. We applied univariate logistic 
regression to determine whether any of the 6 genes with 
differential expression between UC and CDc predicted 
steroid-free clinical remission or response at 6 or 12 
months (Supplementary Table 7). We found that higher 
IL13 expression was associated significantly with an 
increased likelihood of clinical response at 6 (OR, 1.182; 
95% CI, 1.028–1.359) or 12 months (OR, 1.172; 95% CI, 
1.012–1.359), and a trend toward association with clinical 
remission at 12 months (OR, 1.126; 95% CI, 0.978–1.297). 
We then assessed whether the unsupervised clustering 
based on gene expression predicted clinical outcomes in UCFigure 1. Results of microfluidic RT-qPCR gene expression arra
and whisker chart showing gene expression for each target
normalized to median expression of the non-IBD patient group
represent the 95% CI). (B) Principal component analysis plot s
clustering in group 1 and non-IBD in group 2. (C) Dendrogram a
clustering using genes with differential expression between at lea
which shows high expression of IL13, IL5, and IL17A. IL1RL1
soluble versions of the IL33 receptor, respectively. *P < .05, **P <
IBD (all P values are false-discovery rate–corrected).patients. We observed that patients in clusters 1, 2, and 3
were significantly more likely to show clinical response at
6 months (trend for remission), and clinical response and
remission at 12 months, compared with those in clusters 4
and 5 (Table 4). The major distinguishing gene expression
difference between these groups was increased IL13 gene
expression in clusters 1–3 with essentially undetectable
IL13 expression in clusters 4 and 5. Baseline characteristics
and medication exposures by 6 and 12 months were
similar between UC patients in clusters 1–3 compared
with clusters 3 and 4, with the exception of exposure to
anti–tumor necrosis factor (TNF) biologics, which occurred
numerically, but not statistically significantly, more often in
clusters 4 and 5 (Supplementary Table 8). By 6 months,
16.1% of patients in clusters 1–3 and 30.8% of patients in
clusters 4 and 5 were exposed to an anti-TNF biologic drug
(P ¼ .414), and 25.0% of patients in clusters 1–3 and
54.5% of patients in clusters 4 and 5 by 12 months
(P ¼ .131). It is likely that the numerically increased and
earlier infliximab exposure in clusters 4 and 5 is an addi-
tional reflection of the poorer clinical response of this
group to first-line therapies (ie, corticosteroids, mesal-
amine, and thiopurines) compared with that of patients in
clusters 1–3. We did not find any association between
IL13 expression or gene expression cluster and clinical
outcomes in CD.y on rectal mucosal RNA from RISK cohort patients. (A) Box
gene on the array for each IBD diagnostic subphenotype
(boxes represent medians and interquartile range, whiskers
howing separation of 2 groups of patients with UC and CDc
nd heatmap showing the results of unsupervised hierarchical
st 2 diagnosis groups. UC patients aggregate within cluster 2,
(m) and ILRL1(s), transcripts for the membrane-bound and
.01, ***P < .001; #P< .05, ##P < .01, and ###P < .001 vs non-
Figure 2. Real-time RT-qPCR of rectal mucosal RNA from patients in the Cincinnati validation cohort. (A) Box and whisker
chart showing gene expression normalized to median expression of the non-IBD patient group (boxes represent medians and
interquartile range, whiskers represent the 95% CI). (B) Dot plot showing gene expression (normalized to median expression of
the non-IBD patient group) in patients with active UC compared with UC patients with endoscopic healing (each dot repre-
sents a single patient, and lines represent the median). *P < .05, **P < .01, ***P < .001.
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In a well-characterized, treatment-naive, pediatric IBD
inception cohort, we show that the rectal mucosa of pedi-
atric UC patients was distinguished from that of patients
with colon-only Crohn’s disease by increased expression of
genes associated with type 2 and type 17 immune re-
sponses. This finding was not explained by differences in
overall inflammation as measured by S100A8 expression.
Furthermore, in an analysis of prospective data from this
cohort, we show that heightened rectal mucosal IL13
expression at baseline is associated with improved clinical
outcomes in pediatric UC.
The involvement of type 2 inflammation in the patho-
genesis of UC has been debated in the literature. Fuss et al1
first described disparate cytokine secretion from lamina
propria mononuclear cells isolated from surgical specimens
of adults with UC and CD, with those from UC patientsTable 3.Multivariate Logistic Regression for Discriminating
UC From CDc
Gene ORa 95% CI P value
IL5 1.130 1.032–1.238 .009
IL17A 1.196 0.976–1.467 .085
aOdds of a diagnosis of UC over CDc per unit increase in Cq
value for the listed gene.producing increased IL5 and IL13 and those from CD pa-
tients producing interferon-g.1,2 The same group went on to
show that IL13 is produced by natural killer T cells, and that
both IL13 and natural killer T cells disrupt epithelial barrier
function.2,4 Accordingly, we previously showed increased
epithelial activation of signal transducer and activator of
transcription 6, a transcription factor downstream of IL13
signaling, in pediatric UC.15 However, other groups have not
detected increased IL13 production either from lamina
propria mononuclear cells or colon tissue of adult or pedi-
atric patients, respectively, with UC, perhaps because of
differences in the ex vivo experimental techniques for
studies.16,17 Here, we provide strong evidence from a large
well-characterized cohort that mucosal type 2 immune
responses are involved in the early course of pediatric UC.
Our finding of increased IL17A expression in UC is in line
with recent observations by others. The ratio of mucosal
IL17A to IL17F expression has been shown to correlate
significantly with endoscopic disease activity in adult UC.18
In addition, increased dual expression of IL17A by
CD4þCD25- regulatory T cells expressing surface trans-
forming growth factor-b in its latent form (LAPþ) reduces
the suppressor activity of these cells in UC.19
A number of groups have examined the ability of mea-
sures of immune response type to discriminate CD from UC
in adults, but none have made distinctions between CD
anatomic subphenotypes or studied newly diagnosed
treatment-naive patients exclusively.12,20,21 A cross-
sectional study of adult patients from Japan similarly
Figure 3. Logistic regression model including IL5 and IL17A gene expression distinguishing UC from CDc. (A) Receiver
operator curve of logistic regression model. (B) Chart showing estimates of the ORs (odds of UC per unit increase in Cq) and
95% CIs for IL5 and IL17A after bootstrap random sample with replacement internal validation. AUC, area under the curve.showed increased mucosal IL13 gene expression in UC
compared with Crohn’s disease, and that a panel of genes
associated with adaptive immune responses could distin-
guish the two.12 Similarly, another group showed that the
higher mucosal type 2 and lower type 1 T cells as measured
by flow cytometry distinguishes UC from CD in adult
patients.20 By using a discovery cohort of established pa-
tients, they showed that a model including the percentage of
CD4þ T cells positive for interferon-g, T-bet, IL13, and Gata3
was predictive of CD over UC, and validated the model in a
small cohort of newly diagnosed patients. However, in the
former study, tissues samples were taken from both the
colon and the ileum, and in both studies the patients had a
mean disease duration of at least 8 years, were on a variety
of immune-suppressive treatments, and the CD groups
included patients with ileitis, ileocolitis, and colitis. Our
study substantially builds on these prior findings by
showing in a large cohort of newly diagnosed treatment-
naive pediatric patients that rectal type 2 and type 17
gene expression not only distinguishes UC from CD, but
distinguishes UC from colon-only CD. By studying tissues
from newly diagnosed pediatric patients, our findings
provide insight regarding the mucosal immune response
from arguably the earliest practical opportunity in the
disease course to study IBD. Because patients are treat-
ment naive, we are assured that the findings are not influ-
enced by medications with profound effects on immune
function. Furthermore, because colitis-only CD is more
common in children than in adults and can be difficult to
distinguish from UC, our study addresses an important
clinical problem.Some investigators have proposed that Crohn’s colitis
should be considered a distinct disease entity from ileal CD.
A recent genome-wide association study meta-analysis
showed that based on the relative genetic risk for CD vs
UC, CDc and CDic are best characterized as intermediate
phenotypes between UC and CD ileitis (with CDc being in-
termediate between UC and CDic).22 In our immune gene
expression panel, IL17A was expressed intermediately in
CDc and was significantly different from expression in UC
and CDic. CCL11 also showed significantly increased
expression in CDc compared with CDic, similar to in UC. Our
principal component analysis, which incorporates the col-
lective differences from all the genes analyzed, aggregates
CDc patients closer to UC patients, supporting the notion of
CDc representing an intermediate phenotype based on gene
expression as well as genetic make-up.
Contrary to our initial hypothesis, we observed that
pediatric UC patients with a gene expression pattern
marked by increased IL13 expression achieved higher rates
of steroid-free clinical response and remission, and that IL13
gene expression alone was associated directly with clinical
response at 6 and 12 months. The newly diagnosed patients
in this study received standard-of-care treatment at the
discretion of the treating physician. Other groups have
examined markers of adaptive immune responses primarily
with regard to response to anti-TNF therapy in adult UC. In
a cohort of adults patients with UC, higher mucosal IL17A
and IFNG gene expression was associated with remission
after infliximab induction therapy.23 IL13 expression was
not assessed in that study. With regard to markers of type 2






















































































































































































































































































































5.lamina propria T cells in UC patients responding to anti-TNF
agents compared with those without response.20 In addi-
tion, IL13RA2 was among several genes identified in a
mucosal genome-wide expression study as associated with
nonresponse to infliximab in UC.24 We did not observe any
significant associations between IL17A, IFNG, or IL13RA2
and clinical outcomes in this pediatric UC cohort. The dis-
crepancies between our results and those of other groups
likely is owing to our patients being assessed before any
IBD-directed therapy, with many achieving remission on
either mesalamine or immunomodulator drugs. Only one
third of the UC patients in our group were ever exposed to
an anti-TNF drug, whereas the patients in these studies
were refractory to first-line therapies with response
specifically to anti-TNF drugs being assessed.
There are 2 potential explanations as to why increased
mucosal IL13 expression at baseline predicts improved
clinical outcomes. Investigations by our group and others
have supported a pathogenic role for IL13 and type 2 im-
mune responses in human UC and several murine models of
colitis including oxazolone-induced colitis and spontaneous
colitis in Wiskott–Aldrich syndrome protein-deficient and
T-cell–receptor a–deficient mice.2,4,15,25–31 If IL13 indeed is
part of a pathogenic type 2 immune response, then our re-
sults suggest this pathway is suppressed sufficiently by
standard initial therapy, and that a subset of patients with
increased IL13 expression may be more responsive to
treatment. Indeed, we observed that mucosal expression of
IL13 was decreased significantly in patients with therapy-
induced mucosal healing compared with those with active
disease.
However, the failure of 2 phase IIa clinical trials of anti-
IL13 monoclonal antibodies for the treatment of UC to meet
their primary end points draws into question the notion of a
pathogenic role of IL13 in UC (although 1 study did meet
significance for important secondary end points including
clinical remission).32,33 It also is possible that improved
outcomes in high IL13 expressers is the result of a protec-
tive effect exerted by IL13 induced in the context of
inflammation. Among UC patients in this study, we did not
observe a correlation between IL13 and IL17A expression,
suggesting that the production of IL13 may be independent
of a Th17 immune response. Indeed, some groups have
observed beneficial roles for IL13 with regard to epithelial
wound healing and goblet cell function (the latter
particularly with regard to helminth expulsion).34–36 IL10-
deficient mice also deficient for IL13RA2, the gene for a
neutralizing receptor for IL13, show decreased inflamma-
tion when challenged with a parasite or a nonsteroidal anti-
inflammatory drug, suggesting IL13 activity is protective in
these models.37 Finally, IL33-dependent group 2 innate
lymphoid cells that produce IL5, IL13, and the epidermal
growth factor ligand amphiregulin limit inflammation
induced from epithelial damage in dextran sodium sulfate–
induced colitis in mice.38 In line with this last concept, we
observed increased expression of the transcript for
membrane-bound IL33 receptor, one marker of group 2
innate lymphoid cells, in UC compared with both CD and
non-IBD.
There were several notable strengths to our study. First, 
our findings were from newly diagnosed treatment-naive 
pediatric patients, and thus were not influenced by treat-
ment. Second, the cohort was characterized meticulously, 
allowing us to examine distinct CD anatomic subphenotypes. 
Third, the differences we observed were derived from ex-
amination of exclusively rectal samples, all from patients with 
documented rectal involvement. Fourth, we validated gene 
expression differences between colitis diagnoses in an inde-
pendent local cohort. A weakness of this study was that only 
gene expression and not protein abundance was assessed. 
Tissue samples from the RISK cohort were not collected in a 
manner conducive to protein analysis. Although cytokines 
and other proteins may be regulated at the translational or 
post-translational level, cytokine gene expression measured 
by real-time RT-qPCR generally correlates quite well with 
measures of protein abundance.39–41 In addition, although we 
did not observe differences in the expression of the type 1 
cytokine IFNG or transcription factor TBX21 between UC and 
CD, we did not measure expression of other type 1 cytokines 
such as IL12 or TNFB, thus limiting the conclusions we could 
draw regarding the relative contribution of a type 1 immune 
response to UC and CD.
In conclusion, our data support a role for mucosal type 2 
inflammatory responses in the early course of pediatric UC. 
In treatment-naive pediatric patients, UC is distinguished 
from Crohn’s colitis, and specifically colon-only CD by 
increased expression of genes associated with type 2 and 
type 17 immune responses. Furthermore, an immune gene 
expression profile marked by increased expression of the 
type 2 cytokine IL13 is associated with improved clinical 
outcomes in pediatric UC. Future studies are warranted 
from large UC cohorts to determine whether a type 2 gene 
expression predicts response to specific UC therapies with 
the ultimate goal of directing therapies based on patient 
immunophenotype.Supplementary Material
Note: To access the supplementary material accompanying 
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Supplementary Figure 1. Identification of glyceraldehyde-3-phosphate dehydrogenase (GAPDH) as the reference gene with
the least expression variation across diagnosis groups. (A) Dot plot showing the mean Cq and standard errors of 16 candidate
reference genes from an endogenous control real-time RT-qPCR microfluidic array (n ¼ 4 each of non-IBD, CDic, CDc, and
UC). (B) Bar chart showing SDs of the Cq for each candidate reference gene. GAPDH showed the lowest variability in
expression across samples.
Supplementary Figure 2. Analysis of Cincinnati cohort rectal mucosa real-time RT-qPCR controlling for histologic disease
activity. (A) Dot plot of RHI scores for CD and UC patients in the Cincinnati cohort. (B) Dot plot of a subset of CD and UC
patients in the Cincinnati cohort matched on RHI scores. (C) Box and whisker chart showing gene expression normalized to
median expression of the non-IBD patient group in CD and UC patients matched on RHI scores (boxes represent medians and
interquartile range, whiskers represent the 95% CI).
Supplementary Table 1.Targets on Gene Expression Array
Gene Protein function Assay ID
IL4 Type 2 cytokine Hs00174122_m1
IL5 Type 2 cytokine Hs00174200_m1
IL13 Type 2 cytokine Hs00174379_m1
IL13RA2 Type 2 cytokine receptor/protein induced by IL13 Hs00152924_m1
IL33 Cytokine that induces type 2 immune responses Hs01125943_m1
IL1RL1(s) IL33 receptor (soluble) that regulates type 2 immune responses Hs01073297_m1
IL1RL1(m) IL33 receptor (membrane) that induces type 2 immune responses Hs01073295_m1
CCL11 Chemokine associated with eosinophil recruitment and type 2 immune responses Hs00237013_m1
CHI3L1 Protein induced by type 2 immune responses Hs00609691_m1
ICOS T-cell co-stimulatory molecular that augments type 2 immune responses Hs00359999_m1
GATA3 Type 2 T-cell transcription factor Hs00231122_m1
RORA Group 2 innate lymphoid cell transcription factor Hs00536545_m1
CLDN2 Tight junction protein induced by IL13 Hs01549234_m1
IFNG Type 2 cytokine Hs00174143_m1
TBX21 Type 1 transcription factor Hs00203436_m1
IL17A Type 17 cytokine Hs00174383_m1
IL23A Cytokine that augments type 17 immune responses Hs00372324_m1
RORC Type 17 transcription factor Hs01076122_m1
IL22 Type 17 cytokine Hs01574154_m1
AHR Group 3 ILC transcription factor Hs00169233_m1
IL10 T-regulatory cell cytokine Hs00174086_m1
TGFB1 Cytokine that induces T-regulatory cell and type 17 T-cell differentiation Hs00171257_m1
S100A8 Component of calprotectin/marker of inflammation Hs00374264_g1
GAPDH Reference gene Hs99999905_m1
Supplementary Table 2.Comparison Between the Studied RISK Cohort Subset and Overall RISK Cohort
Entire RISK cohort
(N ¼ 1812)

















Age, y 12.7 (9.9, 14.9) 12.8 (10.8, 15.0) 12.7 (9.5, 15.0) 12.4 (10.9, 13.6) 12.4 (9.9, 14.7) 12.7 (10.8, 14.5) 12.5 (9.4, 15.0) 13.5 (10.8, 15.5) 13.1 (10.2, 15.0)
A1a: 0 to <10 y 460 (25.4) 9 (18.4) 116 (28.7) 11 (23.9) 152 (25.1) 6 (17.1) 57 (27.1) 13 (23.2) 49 (24.5)
A1b: 10 to <17 y 1348 (74.6) 39 (79.6) 288 (71.3) 35 (76.1) 454 (74.9) 30 (85.7) 153 (72.9) 43 (76.8) 151 (75.5)
Male sex 1055 (58.2) 23 (46.9) 226 (55.4) 25 (54.3) 377 (62.2) 17 (47.2) 120 (57.1) 30 (53.6) 106 (53.0)
Diagnosis
Non-IBD 408 (22.5) 49 (100) 408 (100) 0 (0) 0 (0) 0 (0) 0 (0) 0 (0) 0 (0)
CD 1118 (61.7) 0 (0) 0 (0) 46 (100) 606 (100) 36 (100) 210 (100) 0 (0) 0 (0)
UC 200 (11.0) 0 (0) 0 (0) 0 (0) 0 (0) 0 (0) 0 (0) 56 (100) 200 (100)
IBD-U 86 (4.7) 0 (0) 0 (0) 0 (0) 0 (0) 0 (0) 0 (0) 0 (0) 0 (0)
CD locationa
L1 181 (16.2) 0 (0) 0 (0) 0 (0) 0 (0)
L2: 210 (18.8) 0 (0) 0 (0) 36 (100) 210 (100)
L3 606 (54.2) 46 (100) 606 (100) 0 (0) 0 (0)
L4 only 18 (1.6) 0 (0) 0 (0) 0 (0) 0 (0)
Insufficient data 103 (9.2) 0 (0) 0 (0) 0 (0) 0 (0)
Upper GI
L4a 531 (47.5) 32 (69.6) 322 (53.1) 17 (47.2) 82 (39.0)
L4b 147 (13.1) 12 (26.1) 97 (16.0) 0 (0) 20 (9.5)
UC extentb
E1 5 (2.5) 2 (3.6) 5 (2.5)
E2 26 (13.0) 7 (12.5) 26 (13.0)
E3 22 (11.0) 7 (12.5) 22 (11.0)
E4 112 (56.0) 36 (64.3) 112 (56.0)
Insufficient data 35 (17.5) 4 (7.1) 35 (17.5)
Macroscopic rectal
involvement
846 (60.3) 46 (100) 409 (67.5) 36 (100) 157 (74.8) 56 (100) 177 (88.5)
PGA
Inactive 50 (3.6) 0 (0) 13 (2.1) 1 (2.8) 11 (5.2) 1 (1.8) 7 (3.5)
Mild 458 (32.6) 11 (23.9) 168 (27.7) 7 (19.4) 62 (29.5) 20 (35.7) 63 (31.5)
Moderate 684 (48.7) 22 (47.8) 324 (53.5) 19 (52.8) 106 (50.5) 23 (41.1) 101 (50.5)
Severe 209 (14.9) 13 (28.3) 98 (16.2) 9 (25.0) 31 (14.8) 12 (21.4) 29 (14.5)
Insufficient data 3 (0.2) 0 (0) 3 (0.5) 0 (0) 0 (0) 0 (0) 0 (0)
PUCAI 45 (30, 60) 45 (35, 60) 45 (30, 60)
Rectal deep ulcers 158 (11.3) 5 (10.9) 75 (12.4) 12 (33.3) 36 (17.1) 10 (17.9) 28 (14.0)
NOTE. Quantitative variables are expressed as medians (quartile 1, quartile 3), and dichotomous variables are shown as n (%).
IBD-U, inflammatory bowel disease unclassified; PUCAI, Pediatric Ulcerative Colitis Activity Index.
aL1, terminal ileal ± limited cecal disease; L2, colonic; L3, ileocolonic; L4, upper gastrointestinal (GI) disease; L4a, upper GI disease proximal to ligament of Treitz, and L4b:
upper GI disease distal to ligament of Treitz.
bE1, ulcerative proctitis; E2, left-sided colitis; E3, extensive colitis; E4, pancolitis.
Supplementary Table 3.Characteristics of the Cincinnati Cohort Patients
Non-IBD (n ¼ 17) CD (n ¼ 20) UC (n ¼ 14)
Age at biopsy collection, y 15.8 (10.5, 16.6) 15.0 (11.2, 6.7) 18.0 (14.5, 19.0)
Male sex 7 (41.2) 15 (75.0) 25 (54.3)
Age at diagnosis, y 10.6 (9.2, 10.6) 14.4 (11.6, 16.5)
A1a: 0 to <10 y 8 (40.0) 3 (21.4)
A1b: 10 to <17 y 11 (55.0) 10 (71.4)
A2: 17–40 y 1 (5.0) 1 (7.1)
Time since diagnosis, y 2.2 (0, 4.7) 2.8 (1.0, 6.2)
Biopsy specimen collected at diagnostic endoscopy 9 (45.0) 0 (0.0)
CD location
L1: terminal ileal ± limited cecal disease 0 (0) 0 (0)
L2: colonic 8 (40.0) 0 (0)
L3: ileocolonic 12 (60.0) 46 (100)
L4a: upper disease proximal to ligament of Treitz 11 (55.0) 32 (69.6)
L4b: upper disease distal to ligament of Treitz 2 (10.0) 12 (26.1)
UC extent
E1: ulcerative proctitis 1 (7.1)
E2: left-sided colitis 3 (21.4)
E3: extensive colitis 3 (21.4)
E4: pancolitis 7 (50.0)
Macroscopic rectal involvement 20 (100) 14 (100)
Clinical disease activity
shPCDAI 25 (12.5, 35)
PUCAI 30 (15, 60)
Endoscopic disease activity 22 (47.8)






None 5 (25.0) 0 (0.0)
Oral corticosteroids 2 (10.0) 7 (50.0)
Rectal corticosteroids 1 (5.0) 2 (14.3)
Oral mesalamine 4 (20.0) 10 (71.4)
Antibiotic 3 (15.0) 0 (0.0)
6-mercaptopurine or azathioprine 5 (25.0) 2 (14.3)
Methotrexate 0 (0.0) 1 (7.1)
Anti-TNF biologic 2 (10.0) 3 (21.4)
NOTE. Quantitative variables are expressed as medians (quartile 1, quartile 3), and dichotomous variables are shown as n (%).
PUCAI, Pediatric Ulcerative Colitis Activity Index; SES-CD, Simple Endoscopic Score for Crohn’s Disease; shPCDAI, Short
Pediatric Crohn’s Disease Activity Index.
Supplementary Table 4.Univariate Logistic Regression for
Discriminating UC From CDc
Gene ORa 95% CI P value
IL5 1.147 1.050–1.644 .003
IL13 1.100 0.998–1.212 .056
IL13RA2 1.311 1.045–1.644 .020
IL1RL1(m) 1.798 1.129–2.865 .014
ICOS 1.435 0.923–2.229 .109
IL17A 1.265 1.032–1.551 .024
IL23A 1.391 1.063–1.821 .016
aOdds of a diagnosis of UC over CDc per unit increase in Cq
value for the listed gene.
Supplementary Table 5.Change in Effect Estimate After




IL5 0.138 0.126 -8.6
IL13 0.095 0.078 -18.1
IL13RA2 0.270 0.332 þ22.8
IL1RL1(m) 0.587 0.561 -4.4
ICOS 0.361 0.277 -23.3
IL17A 0.235 0.232 -1.7
IL23A 0.330 0.328 -0.7
Supplementary Table 6. Inclusion of S100A8 in Multivariate
Logistic Regression Model for
Discriminating UC From CDc
Gene ORa 95% CI P value
IL5 1.133 1.032–1.238 .009
IL17A 1.232 0.976–1.467 .132
S100A8 0.959 0.747–1.233 .747
aOdds of a diagnosis of UC over CDc per unit increase in Cq
value for the listed gene.
Supplementary Table 7.Univariate Logistic Regression of Gene Expression for Predicting UC Clinical Outcomes
Gene
Remission Response
6 month 12 month 6 month 12 month
ORa (95% CI) P value OR (95% CI) P value OR (95% CI) P value OR (95% CI) P value
IL5 1.119 (0.978–1.279) .104 1.050 (0.921–1.198) .466 1.116 (0.981–1.271) .095 1.126 (0.979–1.294) .094
IL13 1.115 (0.973–1.279) .118 1.126 (0.978–1.297) .099 1.182 (1.028–1.359) .019 1.172 (1.012–1.359) .034
IL13RA2 1.350 (0.939–1.942) .105 0.847 (0.595–1.208) .359 1.206 (0.855–1.701) .286 1.046 (0.733–1.493) .804
IL1RL1(m) 1.241 (0.618–2.494) .543 0.716 (0.331–1.550) .397 1.751 (0.786–3.891) .144 0.690 (0.314–1.517) .356
ICOS 1.151 (0.581–2.283) .686 1.198 (0.631–2.273) .582 1.032 (0.515–2.066) .930 1.103 (0.570–2.137) .772
IL17A 1.253 (0.919–1.706) .153 1.111 (0.854–1.445) .433 1.239 (0.929–1.650) .170 1.117 (0.861–1.449) .407
IL23A 1.311 (0.887–1.934) .175 1.071 (0.746–1.538) .711 1.199 (0.813–1.767) .360 1.047 (0.718–1.527) .810
NOTE. Bold text indicates P < .05.
aOdds of outcome per unit increase in Cq value for the listed gene.
Supplementary Table 8.Comparison of Baseline
Characteristics and Medication









Age, y 13.6 (10.7–15.1) 12.2 (11.5–15.8) .813




1 (3.1) 0 (0) .246a
E2: left-sided colitis 2 (6.3) 2 (15.4)
E3: extensive colitis 4 (12.5) 4 (30.8)
E4: pancolitis 25 (78.1) 7 (53.8)
Data not available 1 (3.1) 0 (0)
PGA
Inactive 1 (3.0) 0 (0) .546a
Mild 15 (45.5) 4 (30.8)
Moderate 9 (27.3) 5 (38.5)
Severe 8 (24.2) 4 (30.8)
Rectal deep ulcers 5 (15.6) 2 (15.4) 1.00
Medication exposures
6 months n ¼ 31 n ¼ 13
Corticosteroids 24 (77.4) 12 (92.3) .401
Mesalamine 24 (77.4) 11 (84.6) .703
Thiopurines 10 (32.3) 6 (46.2) .496
Methotrexate 0 (0) 0 (0) –
Anti-TNF biologic 5 (16.1) 4 (30.8) .414
12 months n ¼ 28 n ¼ 11
Corticosteroids 23 (82.1) 0 (90.9) .655
Mesalamine 22 (78.6) 9 (81.8) 1.00
Thiopurines 12 (46.4) 4 (36.4) .725
Methotrexate 1 (3.6) 1 (9.1) .489
Anti-TNF biologic 7 (25.0) 6 (54.5) .131
NOTE. Quantitative variables are expressed as medians
(quartile 1, quartile 3) and dichotomous variables are shown
as n (%).
aFirst 2 groups were combined for the chi-square test.
